Handbook of Clinical medicine

Reticulocyte count 0.8–2.0%1 25–100 ≈ 109/L Erythrocyte sedimentation rate Depends on age (p372) Prothrombin time (citrated bottle) 10–14s (factors I, II, VII, X) Activated partial thrombo- 35–45s plastin time (VIII, IX, XI, XII) Therapeutic ranges for INR: see p351. 1 Only use percentages as reference interval if red cell count is normal; otherwise, use the absolute value. __OOHHCCMM__1100ee..iinnddbb 775544 0022//0055//22001177 1199::0088 .cte ,slavretni ecnerefeR 755 __OOHHCCMM__1100ee..iinnddbb 775555 0022//0055//22001177 1199::0088 .cte ,slavretni ecnerefeR 756 Drug ther apeutic ranges in plasma Ranges should only be used as a guide to treatment. A drug in an apparently too low concentration may still be clinically useful, while some patients require (and tolerate) levels in the ‘toxic’ range. The time since the last dose should be specifi ed on the request form. Amikacin.1 Peak (1h post IV dose): 20–30mg/L. Trough: <10mg/L. Carbamazepine.1 Optimal concentration: 20–50μmol/L (4–12mg/L). Digoxin1 (6–12h post dose) 1–2.6nmol/L (0.8–2mcg/L). <1.3nmol/L may be toxic if there is hypokalaemia. Signs of toxicity—CVS: arrhythmias, heart block. CNS: confu- sion, insomnia, agitation, seeing too much yellow (xanthopsia), delirium. GI: nausea. Gentamicin1,2 (p387) and tobramycin. 1, 2 The potential for oto- and nephrotoxic- ity is high if aminoglycosides are used inappropriately, so only prescribe for short therapeutic
